Hello!

I am a Research Fellow at Memorial Sloan Kettering Cancer Center in the Clinical Genetics Service, led by Dr. Kenneth Offit. My research focuses on identifying the cellular and molecular mechanisms driven by genetic factors, with the ultimate goal of discovering actionable insights for patient treatment.

As a School of Medicine Dean’s Postdoctoral Fellow at Stanford University in Dr. Stephen Montgomery’s lab, I analyzed the largest single-cell multi-omic dataset of fetal Down Syndrome hematopoiesis (with Dr. Ana Cvejic, University of Copenhagen). I discovered a potential mechanistic link between a reshaped chromatin landscape and clinical abnormalities (such as the 150-fold increased risk of childhood leukemia or increased red blood cell counts), which is currently in press at Nature. Additionally, I applied deep learning models to predict the cell-type-specific regulatory effects of both rare and common non-coding variants (with Soumya Kundu & Dr. Anshul Kundaje, ASHG Mtg Presentations ’22, ’24) while leading computational and organizational initiatives within the IGVF Consortium.

Previously, I received my B.S. from Cornell University in Biometry & Statistics, with a minor in Biological Sciences and a concentration in Statistical Genomics. During undergraduate, I completed an Honor’s Thesis in population genetics as a part of Philipp Messer’s group and was a statistical genetics intern at the Regeneron Genetics Center for two summers in Tarrytown, NY. After graduating, I pursued a PhD in the Tri-Institutional Computational Biology & Medicine program, where I researched the genetic basis of human disease using computational and statistical approaches within the labs of Olivier Elemento and Andy Clark at Cornell’s NYC and Ithaca campuses.

Since 2021, I have been consulting for companies such as Pfizer and Third Rock Ventures (Marea Therapeutics). I specialize in integrating human genetics and multi-omic data to advance precision medicine, with a focus on predicting patient response, monitoring disease progression, and identifying potential therapeutic targets.

Long-term, my interests are to use human genetic and multi-omic datasets for (1) therapeutic target discovery, by discovering new genetic associations and their underlying mechanisms; (2) precision medicine, by personalizing treatment regimens based on molecular alterations, and (3) interventive and preventive care, by identifying high-risk individuals for screening & other preventive strategies. I believe we need better conceptual approaches for understanding the genotype-to-phenotype map; as a result, my current research spans both basic and more translational research areas.